Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
First Claim
1. A drug eluting medical device comprising:
- an implantable intraluminal structure;
a pharmaceutically active agent, in therapeutic dosages, affixed to at least a portion of the implantable intraluminal structure; and
a stabilizing agent mixed with the pharmaceutically active agent to substantially hinder degradation thereof through oxidation.
2 Assignments
0 Petitions
Accused Products
Abstract
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism'"'"'s reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism'"'"'s reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices. In each of these instances, antioxidants are utilized to prolong product integrity.
-
Citations
35 Claims
-
1. A drug eluting medical device comprising:
-
an implantable intraluminal structure;
a pharmaceutically active agent, in therapeutic dosages, affixed to at least a portion of the implantable intraluminal structure; and
a stabilizing agent mixed with the pharmaceutically active agent to substantially hinder degradation thereof through oxidation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
-
10. A drug eluting medical device comprising:
-
an implantable intraluminal structure;
a polymeric solution;
a pharmaceutically active agent, in therapeutic dosages, incorporated into the polymeric solution, the resulting mixture being affixed to at least a portion of the implantable intraluminal structure; and
a stabilizing agent incorporated into the resulting mixture to substantially hinder degradation of the pharmaceutically active agent through oxidation. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18)
-
-
19. A drug eluting medical device comprising:
-
an implantable intraluminal structure;
a polymeric solution;
a pharmaceutically active agent, in therapeutic dosages, incorporated into the polymeric solution, the resulting mixture being affixed to at least a portion of the implantable intraluminal structure; and
a stabilizing agent incorporated into the resulting mixture to substantially hinder degradation of the pharmaceutically active agent through oxidation, the stabilizing agent being incorporated into the resulting mixture such that it is proximate the pharmaceutically active agent. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
-
30. A drug eluting medical device comprising:
-
a stent;
a biocompatible polymeric solution;
rapamycin, in therapeutic dosages, incorporated into the polymeric solution, the resulting mixture being affixed to at least a portion of the stent; and
an antioxidant incorporated into the resulting mixture to prevent degradation of the rapamycin. - View Dependent Claims (31, 32, 33, 34, 35)
-
Specification
-
- Resources
-
Current AssigneeWyeth (Pfizer Inc.)
-
Original AssigneeWyeth (Pfizer Inc.)
-
InventorsFennimore, Roy R. Jr.
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current424/423
-
CPC Class CodesA61F 2/07 Stent-graftsA61F 2/91 made from perforated sheet ...A61F 2/954 for placing stents or stent...A61F 2/966 with relative longitudinal ...A61F 2002/067 modularA61F 2002/077 having means to fill the sp...A61F 2250/0067 Means for introducing or re...A61L 2300/416 Anti-neoplastic or anti-pro...A61L 31/143 StabilizersA61L 31/16 Biologically active materia...B23K 2103/42 Plastics B23K2103/16 takes ...B23K 2103/50 Inorganic material, e.g. me...
